That could lead to more delays, says Hazlett, but right now he expects both Strattera and Cymbalta to receive final approval in the second quarter of 2003.

FORBES: Magazine Article

The FDA will probably follow the panel's recommendation--meaning that a combination of Roche's Pegasys and another drug called Copegus could receive final FDA approval by year's end.

FORBES: Magazine Article

The deal, which must still receive regulatory and shareholder approval, is expected to be final in about a year.

FORBES: Focus On The Forbes 500s